Aulin, Linda B. S. http://orcid.org/0000-0003-4840-5704
Tandar, Sebastian T. http://orcid.org/0000-0002-9255-2456
van Zijp, Torben http://orcid.org/0000-0001-6831-4565
van Ballegooie, Etienne
van der Graaf, Piet H.
Saleh, Mohammed A. A. http://orcid.org/0000-0002-0517-6051
Välitalo, Pyry
van Hasselt, J. G. Coen http://orcid.org/0000-0002-1664-7314
Article History
Accepted: 23 October 2022
First Online: 19 November 2022
Declarations
:
: No funding was received for this project.
: No conflict to declare. The views expressed in this manuscript do not necessarily reflect the position of Finnish Medicines Agency.
: A .rar file containing all code related to the PBPK framework is included as supplementary information.
: Not applicable.
: Not applicable.
: L.B.S.A. and J.G.C.H. designed the study; S.T.T. developed the QSAR models, L.B.S.A. , T.Z., E.B. developed the PBPK framework; L.B.S.A performed the data analysis; L.B.S.A, M.A.A.S., P.V., J.G.C.H. supported interpretation of results; L.B.S.A., S.T.T., J.G.C.H., T.Z., E.B., P.H.G., M.A.A.S., P.V., J.G.C.H. wrote the paper; J.G.C.H. conceived the project; all authors reviewed the paper.